Page 43 - David Ricks News Today

Voluntary company price setting isn't a reliable alternative to policy

“The aggressive price cuts we’re announcing today should make a real difference for Americans with diabetes," said Lilly's Chair and CEO David Ricks.

Pharmaceutical giant Eli Lilly said Wednesday it is voluntarily cutting the price of its insulin for all Americans, capping the out of pocket cost for the diabetes treatment at $35 per month or less.

Eli Lilly will cut prices for some older insulins later this year and immediately expand a cap on costs insured patients pay when they fill prescriptions.

“The aggressive price cuts we’re announcing today should make a real difference for Americans with diabetes," said Lilly's Chair and CEO David Ricks.

NPR's Ailsa Chang talks with Eli Lilly CEO David Ricks about the company's move to reduce prices on some older insulins and cap how much people have to pay out of their own pocket.

Drugmaker Eli Lilly announced plans to slash prices on some older insulins, easing the burden on diabetics who need it to survive.

Drugmaker Eli Lilly announced plans to slash prices on some older insulins, easing the burden on diabetics who need it to survive.

Drugmaker Eli Lilly announced plans to slash prices on some older insulins, easing the burden on diabetics who need it to survive.

The announcement comes amid growing federal pressure to lower the cost of insulin prices.